Direava, Developer of AI-Powered Surgical Support Systems, Completes Third-Party Allotment with Sparx, Nissei Capital, and SBI Investment to Accelerate Physical AI Development in Surgery

Direava Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Yuji Takeuchi; hereinafter 'Direava') announces the completion of a third-party allotment of shares with Sparx Asset Management Co., Ltd., which manages the 'Future Creation No. 3 Fund'; Nissei Capital Co., Ltd., which manages the 'Nissei Capital No. 15 Investment Limited Partnership'; and SBI Investment Co., Ltd., which manages the 'SBI Venture Fund 2023A Investment Limited Partnership' and 'SBI Venture Fund 2023B Investment Limited Partnership', as underwriters. Leveraging this fundraising, the company will further accelerate research and development of Physical AI in the field of surgical procedures and begin full-scale construction of a global business foundation. The primary uses of the funds raised include: advancing core 'Physical AI' technologies aimed at automated surgery; full-scale expansion into overseas markets, primarily the US and Europe, and strengthening regulatory compliance systems such as the FDA; and intensifying recruitment of highly skilled AI and medical professionals both domestically and internationally. CEO Yuji Takeuchi commented that following the previous Series A round, he is honored to receive continued support from Nissei and SBI, and to welcome Sparx as a new top-tier investor. He stated that while Direava achieved regulatory approval for its first product at the end of 2025, their goal extends beyond on-screen guidance; through the implementation of Physical AI, they aim to support surgeons and realize safer, more reproducible medical care. Investor comments include: Kosuke Tatsumi, Vice President of the Next-Generation Growth Investment Division at Sparx Asset Management, expressed that surgical support AI based on high-quality surgical data from Japanese doctors, and the subsequent realization of Physical AI, are essential for improving global medical standards. He expressed confidence in CEO Takeuchi's track record as an outstanding surgeon and his strong entrepreneurship. Yi Rong, Capitalist at Nissei Capital, noted that Direava's first product, 'Kinosura', received regulatory approval at the end of 2025 and is evolving into a generative AI specialized for surgery. He praised the company's business growth in achieving milestones on schedule. Koji Maruyama, Executive Officer and Head of Investment Department at SBI Investment, stated that one year after their initial investment, Direava has shown progress exceeding expectations in both business and development, and he looks forward to its global expansion and contribution to solving social issues. Direava is currently actively recruiting for sales and engineering positions.